NCT00532090View on ClinicalTrials.gov

A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Neoplasms
Interventions
DRUG

RG4733

Administered orally daily at ascending doses to successive cohorts of patients

DRUG

RG4733

Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule

DRUG

RG4733

Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle

Trial Locations (7)

77030

Houston

80045

Aurora

98229

San Antonio

02114

Boston

02115

Boston

02215

Boston

08901

New Brunswick

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00532090 - A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter